Journal
NATURE NANOTECHNOLOGY
Volume 6, Issue 10, Pages 645-650Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/NNANO.2011.153
Keywords
-
Funding
- Safeway Foundation
- Providence Portland Medical Foundation
- Oregon Nanoscience and Microtechnologies Institute
- National Science Foundation
- National Institutes of Health [R01CA107243, R21CA141278]
- Directorate For Engineering
- Div Of Electrical, Commun & Cyber Sys [1057565] Funding Source: National Science Foundation
Ask authors/readers for more resources
Therapeutic cancer vaccination is an attractive strategy because it induces T cells of the immune system to recognize and kill tumour cells in cancer patients. However, it remains difficult to generate large numbers of T cells that can recognize the antigens on cancer cells using conventional vaccine carrier systems(1,2). Here we show that alpha-Al2O3 nanoparticles can act as an antigen carrier to reduce the amount of antigen required to activate T cells in vitro and in vivo. We found that alpha-Al2O3 nanoparticles delivered antigens to autophagosomes in dendritic cells, which then presented the antigens to T cells through autophagy. Immunization of mice with alpha-Al2O3 nanoparticles that are conjugated to either a model tumour antigen or autophagosomes derived from tumour cells resulted in tumour regression. These results suggest that alpha-Al2O3 nanoparticles may be a promising adjuvant in the development of therapeutic cancer vaccines.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available